Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
24 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Lumosa Therapeutics Co., Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Lumosa Therapeutics Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Lumosa Therapeutics Co., Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Lumosa Therapeutics Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Lumosa Therapeutics Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Lumosa Therapeutics Co., Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Lumosa Therapeutics Co., Ltd.'s pipeline products Reasons to buy - Evaluate Lumosa Therapeutics Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Lumosa Therapeutics Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Lumosa Therapeutics Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Lumosa Therapeutics Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lumosa Therapeutics Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Lumosa Therapeutics Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Lumosa Therapeutics Co., Ltd. Snapshot 4 Lumosa Therapeutics Co., Ltd. Overview 4 Key Information 4 Key Facts 4 Lumosa Therapeutics Co., Ltd. - Research and Development Overview 5 Key Therapeutic Areas 5 Lumosa Therapeutics Co., Ltd. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Lumosa Therapeutics Co., Ltd. - Pipeline Products Glance 9 Lumosa Therapeutics Co., Ltd. - Late Stage Pipeline Products 9 Phase III Products/Combination Treatment Modalities 9 Lumosa Therapeutics Co., Ltd. - Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 Lumosa Therapeutics Co., Ltd. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Lumosa Therapeutics Co., Ltd. - Drug Profiles 12 LT-1001 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 STD-07 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 LT-2001 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 LT-3001 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 STD-06 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Lumosa Therapeutics Co., Ltd. - Pipeline Analysis 17 Lumosa Therapeutics Co., Ltd. - Pipeline Products by Target 17 Lumosa Therapeutics Co., Ltd. - Pipeline Products by Route of Administration 18 Lumosa Therapeutics Co., Ltd. - Pipeline Products by Molecule Type 19 Lumosa Therapeutics Co., Ltd. - Pipeline Products by Mechanism of Action 20 Lumosa Therapeutics Co., Ltd. - Dormant Projects 21 Lumosa Therapeutics Co., Ltd. - Locations And Subsidiaries 22 Head Office 22 Appendix 23 Methodology 23 Coverage 23 Secondary Research 23 Primary Research 23 Expert Panel Validation 23 Contact Us 24 Disclaimer 24
List of Tables Lumosa Therapeutics Co., Ltd., Key Information 4 Lumosa Therapeutics Co., Ltd., Key Facts 4 Lumosa Therapeutics Co., Ltd. - Pipeline by Indication, 2014 6 Lumosa Therapeutics Co., Ltd. - Pipeline by Stage of Development, 2014 7 Lumosa Therapeutics Co., Ltd. - Monotherapy Products in Pipeline, 2014 8 Lumosa Therapeutics Co., Ltd. - Phase III, 2014 9 Lumosa Therapeutics Co., Ltd. - Phase I, 2014 10 Lumosa Therapeutics Co., Ltd. - Preclinical, 2014 11 Lumosa Therapeutics Co., Ltd. - Pipeline by Target, 2014 17 Lumosa Therapeutics Co., Ltd. - Pipeline by Route of Administration, 2014 18 Lumosa Therapeutics Co., Ltd. - Pipeline by Molecule Type, 2014 19 Lumosa Therapeutics Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 20 Lumosa Therapeutics Co., Ltd. - Dormant Developmental Projects,2014 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.